Objective: To reanalyze data from two previous studies to provide stronger evidence of benefit for early use of single-dose intravenous bolus salbutamol in children with acute severe exacerbations ...

It is approved for administration as a single 5-second IV bolus. The FDA has approved TNKase, a tissue plasminogen, clot-dissolving agent, to treat acute ischemic stroke in adults, according to ...

It is delivered as a single five-second intravenous (IV) bolus, a faster and simpler administration compared to the standard-of-care Activase, which is administered as an IV bolus followed by a 60 ...

TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS ...

See literature. Early treatment: initially administer three 5mg IV bolus inj given at approximately 2-minute intervals; monitor BP, HR, ECG. If full IV dose (15mg) tolerable, give 50mg (tab ...

[27] We consider the use of a single-dose intravenous salbutamol bolus in the ED to be more effective in achieving earlier clinical response in a subgroup of children with acute severe asthma.

TNKase is delivered as a single five-second intravenous bolus. This is considerably faster than the standard of care, Activase (alteplase), which is administered as an intravenous bolus followed by a ...

The 5-second intravenous bolus offers faster, simpler administration than Activase. (HealthDay News) — The US Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or ...

TNKase is delivered as a single five-second intravenous bolus. This is considerably faster than the standard of care, Activase (alteplase), which is administered as an intravenous bolus followed ...